Gene Therapy Cos. Settle Patent Suit
The LentiVector technology at issue is used to safely deliver beneficial genes to target cells for research and therapeutic purposes.
Under the deal announced on Friday, Oxford BioMedica will license patents underlying its LentiVector technology to Open Biosystems for research. Other terms of the agreement were deemed confidential...
To view the full article, register now.